Profile: Alimera Sciences Inc (ALIM.O)
12 Mar 2014
Alimera Sciences, Inc. (Alimera), incorporated on June 4, 2003, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is focused on diseases affecting the back of the eye, or retina. The Company's product candidate is ILUVIEN. ILUVIEN is inserted in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. ILUVIEN is also being studied in three Phase 2 clinical trials for the treatment of the dry form of age-related macular degeneration (AMD), the wet form of AMD and retinal vein occlusion (RVO).
The Company's product candidate, ILUVIEN, is an intravitreal implant providing a therapeutic effect for up to 36 months in the treatment of vision impairment associated with diabetic macular edema (DME) by delivering sustained sub-microgram levels of Fluocinolone acetonide (FAc), which is a non-proprietary corticosteroid. FAc is an active compound in ILUVIEN and a member of the class of steroids known as corticosteroids. ILUVIEN consists of a tiny polyimide tube with a membrane cap, licensed by the Company from pSivida US, Inc. (pSivida).
The Company competes with MacuSight, Inc., Thrombogenics NV and Novagali Pharma S.A.
Alimera Sciences Inc
Suite 290, 6120 Windward Parkway
ALPHARETTA GA 30005